Role of Tyrosine Kinase Inhibitors in Modulating Chondrocyte Activity and Cartilage Diseases

Area of Science:

• Biochemistry
• Pharmacology
• Rheumatology

Background:

• Tyrosine kinases (TK) regulate critical joint cellular processes including proliferation, differentiation, and apoptosis.
• Dysregulation of TK pathways contributes to cartilage degeneration and inflammation in joint diseases.
• Current treatments for inflammatory and degenerative joint disorders have limitations.

Purpose of the Study:

• To review the role of tyrosine kinase inhibitors (TKIs) in modulating chondrocyte activity.
• To explore the therapeutic potential of TKIs in cartilage-related diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA).
• To assess the current status and challenges of TKI utilization in joint disease management.

Main Methods:

• A literature search was conducted in PubMed and Google Scholar.
• Keywords used included: cartilage regeneration, chondrocyte activity, OA, RA, and TK inhibitors.
• Relevant publications were synthesized to construct the review.

Main Results:

• TK inhibitors demonstrate anti-inflammatory effects via multiple pathways, aiding in cartilage disease treatment.
• Specific TKIs like tofacitinib and baricitinib are approved for RA; others are under investigation for RA and OA.
• TKIs offer potential for managing inflammatory and degenerative joint disorders.

Conclusions:

• TK inhibitors represent a promising therapeutic strategy for joint diseases, potentially improving management and promoting cartilage regeneration.
• Challenges include serious side effects, limited joint specificity, and insufficient clinical research.
• Further investigation is warranted to optimize TKI therapy for joint conditions.